Sana Biotechnology results from the phase 1 study using SC291 for the treatment of patients with SLE are expected in 2025.
A Karolinska Institutet study revealed that individuals with frontotemporal dementia exhibit reduced brain activity when ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback